Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. (Q53626399)

16 May 2018

title

Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. (English)

1 reference

16 May 2018

0 references

1 reference

M Tarzi

1

1 reference

16 May 2018

S Klunker

2

1 reference

16 May 2018

C Texier

3

1 reference

16 May 2018

A Verhoef

4

1 reference

16 May 2018

S O Stapel

5

1 reference

16 May 2018

C A Akdis

6

1 reference

16 May 2018

B Maillere

7

1 reference

16 May 2018

A B Kay

8

1 reference

16 May 2018

M Larché

9

1 reference

16 May 2018

publication date

1 April 2006

1 reference

16 May 2018

Clinical & Experimental Allergy

published in

1 reference

16 May 2018

volume

36

1 reference

16 May 2018

issue

4

1 reference

16 May 2018

page(s)

465-474

1 reference

16 May 2018

Long-term clinical efficacy of grass-pollen immunotherapy

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

Immunotherapy in asthma: an updated systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

Peptide immunotherapy for allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

Effects of peptide therapy on ex vivo T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

The safety and efficacy of ALLERVAX CAT in cat allergic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor β2 subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02469.X

10.1111/J.1365-2222.2006.02469.X

21 January 2018

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018